Skip to main content

Congress, the FDA, and the fair development of new medications for children.

Publication ,  Journal Article
McKinney, RE
Published in: Pediatrics
September 2003

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pediatrics

DOI

EISSN

1098-4275

Publication Date

September 2003

Volume

112

Issue

3 Pt 1

Start / End Page

669 / 670

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Pharmaceutical Preparations
  • Pediatrics
  • Orphan Drug Production
  • Legislation, Drug
  • Humans
  • Drug Labeling
  • Drug Industry
  • Drug Design
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McKinney, R. E. (2003). Congress, the FDA, and the fair development of new medications for children. Pediatrics, 112(3 Pt 1), 669–670. https://doi.org/10.1542/peds.112.3.669
McKinney, Ross E. “Congress, the FDA, and the fair development of new medications for children.Pediatrics 112, no. 3 Pt 1 (September 2003): 669–70. https://doi.org/10.1542/peds.112.3.669.
McKinney RE. Congress, the FDA, and the fair development of new medications for children. Pediatrics. 2003 Sep;112(3 Pt 1):669–70.
McKinney, Ross E. “Congress, the FDA, and the fair development of new medications for children.Pediatrics, vol. 112, no. 3 Pt 1, Sept. 2003, pp. 669–70. Pubmed, doi:10.1542/peds.112.3.669.
McKinney RE. Congress, the FDA, and the fair development of new medications for children. Pediatrics. 2003 Sep;112(3 Pt 1):669–670.

Published In

Pediatrics

DOI

EISSN

1098-4275

Publication Date

September 2003

Volume

112

Issue

3 Pt 1

Start / End Page

669 / 670

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Pharmaceutical Preparations
  • Pediatrics
  • Orphan Drug Production
  • Legislation, Drug
  • Humans
  • Drug Labeling
  • Drug Industry
  • Drug Design